• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Oregon State University receives National Science Foundation grant

August 31, 2022
dvm360 Staff

The $250,00 grant will help the veterinary college in its development of antibody treatment for canines with cancer

Oregon State University Carlson College of Veterinary Medicine announced that thanks to funding provided in a grant from the National Science Foundation, its researchers can move forward in developing a specialized antibody treatment for dogs with cancer. Through this treatment, canines will have an effective, gentler, and more targeted approach to fighting cancer, like immunotherapeutic use to treat people suffering from cancer.

“It’s not a drug like chemotherapy where it’s a toxin. You’re actually recruiting the body’s natural immune response for clearing out transformed cells — for instance, a tumor — and then it kills them,” said Dan Mourich, PhD, senior OSU research associate and the molecular biologist on the research team, in an organizational release.1

According to the release, the research team consists of Chris Cebra, VMD, MA, MS, DACVIM, camelid expert and the chair of the clinical sciences department in OSU’s veterinary college, Shay Bracha, DVM, MS, former OSU professor and clinical veterinary oncologist, and Carl Ruby, PhD, a veterinary pharmacology instructor at OSU.

When it comes to the research, it was developed through unlikely collaborators, OSU’s llamas and alpacas that are in the camelid family. According to the release,1 the research teams injected a protein found within canine tumors which then provoked the animal’s immune system to create a specific antibody in response to the protein. Then, researchers screened a ‘genetic library’ of the results to help determine which antibodies were the most effective at binding and blocking tumors from interacting with a dog's cytotoxic killer T-cells.

Advertisement

With this grant, researchers will be able to develop a clinical candidate and establish the treatment's production method, which will then lead to a clinical trial to test the treatment's effectiveness.

“The efficacy of immune-based therapeutics has already been tested in the human clinic for cancer and other diseases, but we’re not going to take human drugs and try to adapt them to the dog. We’re going to make the dog drug that does the same thing,” expressed Mourich.

Reference

NSF grant to OSU researchers will aid development of antibody treatment for dogs with cancer. News release. Oregon State University. August 25, 2022. Accessed August, 31, 2022. https://today.oregonstate.edu/news/nsf-grant-osu-researchers-will-aid-development-antibody-treatment-dogs-cancer

Related Content:

ClinicalOncology
Morris Animal Foundation funds study on environmental toxins and lymphoma
Morris Animal Foundation funds study on environmental toxins and lymphoma
Study evaluating potential treatment for degenerative myelopathy receives funding
Study evaluating potential treatment for degenerative myelopathy receives funding
Alternate therapies for pain management
Alternate therapies for pain management

Advertisement

Latest News

Locoregional analgesia for pain management in veterinary medicine

Outside toxicology experts can save pets’ lives

Lyon College School of Veterinary Medicine names founding dean

Morris Animal Foundation funds study on environmental toxins and lymphoma

View More Latest News
Advertisement